Changing Agendas on Sleep, Treatment and Learning in Childhood Epilepsy (CASTLE)

<– Visit our Patient Public Involvement page on the left to read about the work we are doing to support Purple Day 2018

 

Welcome to our research website…

The CASTLE study is focused on rolandic epilepsy, which is the most common type of childhood epilepsy and affects about one-sixth of all children with epilepsy in the UK.

Throughout the CASTLE study, we’ll be working with children, parents, doctors and nurses to choose the best ways to measure health and quality of life for children with epilepsy. The research will also include talking to parents and children about their experiences in relation to sleep, taking medication, learning and how taking part in the study has impacted on them.

Our studies

Core Health Outcomes In Childhood Epilepsy (CHOICE)

The Core Health Outcomes In Childhood Epilepsy (CHOICE) study is seeking consensus agreement on which outcomes are most important to measure for children with the most common type of epilepsy.

FIND OUT MORE

Qualitative Study

In this part of the study, children and parents are asked to tell us about their experiences of living with rolandic epilepsy. We’re interested to learn about their experiences of taking the study medication, how they/their child is sleeping, and the impact of epilepsy on them/their child’s learning.

FIND OUT MORE

Sleep Intervention

Are you the parent of a child aged 5-12 years who has epilepsy and has experienced sleeplessness problems either currently or in the past? We want to find out, from parents, what they think we should include or leave out of our sleep intervention.

FIND OUT MORE

Clinical Trial

We have designed this clinical trial in such a way that everyone has an equal chance of being treated with one of the drug/non-drug options, as well as having a 50:50 chance of trying our sleep package.

FIND OUT MORE

Collaborators

Without the generosity of people and funding bodies our research would not be possible. We acknowledge and we are very grateful to our funders and partners.